Determinants of 12-month non-persistence (Cox model)
| Hazard Ratio | IC 95% | P-value | ||
|---|---|---|---|---|
| SC-TNFis | ||||
| GLM | 1.000 | – | – | – |
| CZP | 2.315 | 1.438 | 3.726 | 0.0005 |
| ETA | 1.631 | 1.199 | 2.217 | 0.0018 |
| ADA | 1.167 | 0.944 | 1.443 | 0.1525 |
| Sex | ||||
| Male | 1.000 | – | – | – |
| Female | 1.480 | 1.301 | 1.684 | <0.0001 |
| Age | 0.996 | 0.991 | 1.001 | 0.1544 |
| Deprived socio-economic status : Yes vs No | 1.486 | 1.197 | 1.843 | 0.0003 |
| Number of comorbid conditions (per additional condition) | 0.993 | 0.885 | 1.115 | 0.9114 |
| Biotherapy line (per additional line) | 1.422 | 1.188 | 1.702 | 0.0001 |
| DMARD dispensation: Yes vs No | 0.965 | 0.854 | 1.090 | 0.5649 |
| Sulfasalazine dispensation : Yes vs No | 1.127 | 0.907 | 1.401 | 0.2789 |
| Long-term oral steroids : Yes vs No | 1.101 | 0.918 | 1.320 | 0.2980 |
| Hospital admission for IRMD | 0.784 | 0.611 | 1.007 | 0.0565 |
| Visits to rheumatologist | ||||
| 0 | 1.000 | – | – | – |
| 1–4 | 0.808 | 0.598 | 1.093 | 0.1673 |
| >4 | 0.779 | 0.577 | 1.052 | 0.1035 |
| Interaction with time | ||||
| Interaction biotherapy * time | 1.001 | 1.001 | 1.002 | 0.0013 |
| Interaction comorbid conditions * time | 1.001 | 1.000 | 1.001 | 0.0138 |
| Interaction biotherapy line * time | 0.998 | 0.997 | 0.999 | 0.0006 |
| Interaction hospital admission for IRMD * time | 1.002 | 1.000 | 1.003 | 0.0303 |